NICE guidance (NG28) recommends GLP-1 receptor agonists as a treatment option for adults with type 2 diabetes when: Triple therapy with metformin and two other oral drugs is not effective, not tolerated or contraindicated The person has a BMI of 35 kg/m or higher (adjust accordingly for people from particular ethnic groups) and specific psychological or other medical problems associated with obesity The person has a BMI lower than 35 kg/m and insulin would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities GLP-1 receptor agonists may also be considered in combination with insulin therapy in specialist care settings Beyond glycaemic control, specific GLP-1 receptor agonists offer significant cardiovascular benefits
A standout example is tirzepatide, a co-agonist at the receptors for GLP-1 and GIP
We work closely with you to understand your unique needs and develop a customized treatment plan
Losing weight improves your insulin sensitivity, which, in turn, helps preserve muscle mass
Servings per container: 50
For those interested in conversion between different GLP-1 formulations , the general principle is to prioritize symptom management over dose equivalence
